Pre-treatment vitamin D insufficiency predicts severe paclitaxel-induced sensory neuropathy in breast cancer patients: a prospective cohort study

Amany M. Elfeky, Muhammad I. El-Masry, Amr A. Mahmoud, Sara A. Amin, Rana El Falah, Mo’men M. Saadoun · 2026

Read Pre-treatment vitamin D insufficiency predicts severe paclitaxel-induced sensory neuropathy in breast cancer patients: a prospective cohort study by Amany M. Elfeky, Muhammad I. El-Masry, Amr A. Mahmoud, Sara A. Amin, Rana El Falah, Mo’men M. Saadoun (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13144410.txt.

Description

A common chemotherapy drug damages feeling in hands and feet, and low vitamin D beforehand may forecast the worst cases. Amany Elfeky and co-authors followed that forecast in this 2026 study. Three hundred breast cancer patients starting paclitaxel treatment joined the prospective cohort. Vitamin D was measured in blood before treatment began.

The drug's nerve damage strikes up to seventy percent of patients, severely in about thirty percent. Age and genes were known risks but cannot be changed. Vitamin status can be corrected, which makes it a practical lead. Twelve weeks of weekly treatment were tracked for severe sensory symptoms. A cheap blood test at intake could flag who needs closer watching.

Catalog record

CREATORAmany M. Elfeky, Muhammad I. El-Masry, Amr A. Mahmoud, Sara A. Amin, Rana El Falah, Mo’men M. Saadoun
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE55 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13144410

Browse the full library · About the Tower of Babel